BioSpace News Archive

Announcement of investment in Resilience Biotechnologies Inc. will improve Canada’s future pandemic preparedness

The Ivy Rehab Network, a national leader in outpatient musculoskeletal rehabilitative services, is proud to announce it has joined Cigna as an in-network provider in six states, effective May 17th.

ClearPoint Neuro, Inc., a global therapy-enabling company providing navigation and delivery to the brain, announced the first human cases of the SmartFrame Array Neuro Navigation System and Software.

Virtual KOL event to focus on the unmet medical need in relapsed/refractory EBV-positive lymphoma and the design of NAVAL-1, a global pivotal trial Event to take place on Thursday, May 20th at 2:00 PM ET

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Oppenheimer MedTech, Tools & Diagnostics Summit on Wednesday, May 26, 2021.

Leading vendors of analytics are paving the way for investments and adoption of analytics technology by accelerating the modernization process and decision-making to become more data-driven, according to Nucleus Research’s Analytics Technology Value Matrix 2021.

Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company’s trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, to its overall survival (OS) primary endpoint.

CVS Health announced it has appointed Shawn Guertin as Executive Vice President and Chief Financial Officer, effective May 28, 2021.

-- Lipid-polymer nanocomplexes (LPNCs) developed by Mirus enable superior transfection performance in a range of delivery applications -- Investment will support GMP launch of TransIT VirusGEN for high-productivity, cell-adaptive transfection in viral vector manufacturing -- Highly complementary engineering and delivery capabilities extend Gamma’s advanced therapy offering

-- Results demonstrate NKTR-255’s differentiated pharmacologic profile versus precomplexed IL-15 agonists, supporting its potential as a potent immunotherapy agent --